20MO Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician’s choice (TPC)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer

“…A post-hoc analysis showed that time to first deterioration was generally similar between arms for most functional scores, with time to definitive deterioration favoring the ICI plus TKI combination for most assessed scales. 43 Grade ⩾3 adverse events (AEs) occurred in 88.9% versus 72.7%, AEs leading to treatment discontinuation occurred in 33.0% versus 8.0%, and deaths due to treatment-related AEs (TRAEs) occurred in 1.5% versus 2.1% of patients, respectively ( Table 3 ). The most common grade ⩾3 TRAEs for the ICI plus TKI combination were hypertension (35.9%), diarrhea (6.2%), weight loss (5.9%), and decreased appetite (5.9%).…”

“…Despite higher rates of discontinuation of any treatment due to TRAEs reported with the combination of pembrolizumab and lenvatinib compared with chemotherapy (26.6% versus 5.7%) ( Table 3 ), no substantial differences in QoL were measured by the QLQ-C30 global health status scores, 36 and a post-hoc analysis showed that the combination delayed the time to definitive QoL deterioration with benefits observed in most of the scales assessed. 43 However, the QLQ-C30 is designed for heterogeneous cancer populations, thus could lead to measurement non-invariance and biased group comparisons. 52 Finally, the 20 mg starting dose of lenvatinib used in this trial is controversial, a topic which is discussed in greater detail below.…”